The intentional inclusion of SCLC-specific biomarkers like ProGRP and NSE, despite our cohort’s focus on NSCLC and benign conditions, was to enhance the model’s clinical realism and preparedness for distinguishing NSCLC from SCLC in future applications, positioning it as a comprehensive triage tool rather than a simple NSCLC detector. The gene discussed is ENO2; the disease is small cell lung carcinoma.